Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAK Hiperglikemia adalah efek samping yang umum kombinasi steroid dan L-asparaginase, terjadi paling sering selama kemoterapi fase induksi LLA. Sampai saat ini di Indonesia, belum didapatkan data mengenai kejadian hiperglikemia pada pasien anak dengan LLA pada fase induksi dan bagaimana peranan perbedaan kombinasi L-asparaginase dan jenis steroid yang digunakan.Tujuan penelitian ini adalah untuk mengetahui angka kejadian hiperglikemia pada anak LLA fase induksi, perbedaan prednison dan deksametason dalam kombinasinya dengan L-asparaginase dalam menyebabkan hiperglikemia pada anak dengan LLA dan hubungan faktor-faktor lain dengan kejadian hiperglikemia pada fase induksi LLA.Penelitian ini merupakan studi prospektif analitik dengan desain pre-post test, dilakukan di RSCM, RS Kanker ldquo;Dharmais rdquo; dan RSPAD Gatot Soebroto. Pasien yang akan menjalani kemoterapi fase induksi LLA diperiksa kadar gula darah sewaktu pada minggu ke-3 pretest , minggu ke-4, minggu ke-5 dan minggu ke-6 protokol post test .Dari 57 pasien yang berasal dari 3 Rumah Sakit yang berbeda berhasil dikumpulkan, terbanyak berasal dari RSCM 57,9 disusul RS Kanker ldquo;Dharmais rdquo; 24,6 dan RSPAD Gatot Soebroto 17,5 . Rentang umur pasien berkisar antara 1,4 tahun sampai 15,8 tahun dengan rerata 6,7 tahun. Tidak terdapat perbedaan rerata kadar gula darah sewaktu sebelum dan sesudah kombinasi steroid dan L-asparaginase. Tidak didapatkan hubungan antara umur, infiltrasi SSP, leukositosis, sindrom Down, status gizi, riwayat DM pada keluarga, infeksi dan stratifikasi LLA dengan kejadian hiperglikemia. Pemberian deksametason memiliki peluang 10,68 x didapatnya angka di atas rerata perubahan kadar gula darah sewaktu dibandingkan pemberian prednison.Kesimpulan: kejadian hiperglikemia pada penelitian ini adalah 5,2 . Walaupun tidak terdapat perbedaan antara prednison dan deksametason dalam kombinasinya dengan L-asparaginase dalam menyebabkan hiperglikemia, namun deksametason memiliki risiko angka di atas rerata perubahan kadar gula darah sewaktu dibandingkan prednison.

---

ABSTRACTHyperglycaemia is a common side effect of steroid and L asparaginase combinations, occurring most often during LLA induction phase. To date in Indonesia, it has not been obtained data on the incidence of hyperglycemia in children with LLA in the induction phase and how the role of combinations of L asparaginase and different type of steroid used.The purpose of this study is to determine the incidence of hyperglycemia in children LLA induction phase, knowing the difference between prednisone and dexamethasone in combination with L asparaginase in causing hyperglycemia in children with LLA and determine the relationship of other factors related to hyperglycaemia.This study is a prospective analytic study with pre post test design, conducted in RSCM, National Cancer Hospital Dharmais and RSPAD Gatot Soebroto. When undergoing chemotherapy induction phase LLA, blood sugar levels were checked at the 3rd pretest , 4th, 5th and 6th week of protocol post test .Of the 57 patients from three different hospitals that had been gathered, mostly came from RSCM 57.9 followed by the Cancer Hospital Dharmais 24.6 and RSPAD 17.5 . The patient age ranged from 1.4 years to 15.8 years with a mean of 6.7 years. There was no difference in mean blood sugar levels before and after combination of steroids and L asparaginase. There were no relationship between age, CNS infiltration, leukocytosis, Down syndrome, nutritional status, family history of diabetes, infections and LLA stratification with the incidence of hyperglycemia. Dexamethasone has a 10.68 x chance of obtaining a rate above the mean change in blood sugar levels compared to prednisone.Conclusion The incidence of hyperglycemia in this study is 5.26 . Despite no difference between prednisone and dexamethasone in combination with L asparaginase in causing hiperglycaemia, but dexamethasone has a risk to have value above the mean change in blood sugar levels when compared to prednisone."

"Latar belakang. Anak dan remaja dengan leukemia limfoblastik akut (LLA) berisiko mengalami osteoporosis sekunder, salah satunya karena pemberian obat kemoterapi metotreksat dan steroid. Saat ini belum terdapat data prevalens osteoporosis sekunder pada anak dengan LLA di Indonesia dan bukti keterkaitan dosis kumulatif metotreksat dan steroid terhadap kejadian osteoporosis sekunder pada anak dengan LLA.Tujuan. Mengetahui ada tidaknya kaitan antara dosis kumulatif metotreksat dan/atau steroid terhadap kejadian osteoporosis sekunder pada anak dan remaja dengan LLA.Metode. Penelitian ini merupakan studi potong lintang terhadap 52 anak dan remaja dengan LLA yang sedang menjalani kemoterapi di Rumah Sakit dr. Cipto Mangunkusumo (RSCM). Pengambilan darah dan foto polos tulang belakang dilakukan untuk menilai parameter kesehatan tulang, serta pemeriksaan dual energy X-ray absorptiometry (DEXA) untuk menilai densitas mineral tulang. Analisis regresi logistik digunakan untuk menganalisis keterkaitan dosis kumulatif metotreksat dan steroid terhadap kejadian osteoporosis sekunder.Hasil. Median usia subyek adalah 10 (7-14) tahun dengan lelaki 54% (n=52). Didapatkan kejadian osteoporosis sekunder 6/52 (11,5%) dan densitas mineral tulang rendah 11/52 (21,2%). Tidak didapatkan kaitan antara dosis kumulatif steroid (adjusted RP 0,474 [0,057-3,935], p = 0,489) dan dosis kumulatif metotreksat (adjusted RP 0,083 [0,006-1,126], p = 0,061)  dengan kejadian osteoporosis sekunder. Pasien berusia di bawah 10 tahun, memiliki kadar vitamin D rendah, dan status prepubertas memiliki kecenderungan mengalami osteoporosis sekunder.Kesimpulan. Tidak didapatkan hubungan yang bermakna secara statistik antara dosis kumulatif steroid dan/atau metotreksat terhadap osteoporosis sekunder pada anak dan remaja dengan LLA.

---

Background. Children and adolescents with acute lymphoblastic leukemia (ALL) are at risk of secondary risk, one of which is the administration of chemotherapy drugs (methotrexate and steroids). Currently, there are no data on the prevalence of secondary osteoporosis in children with ALL in Indonesia and evidence about association between methotrexate and steroids with the incidence of secondary osteoporosis with ALL.

Objective. To determine whether there is an association between the cumulative dose of methotrexate and/or steroids on the incidence of secondary osteoporosis in children and adolescents with ALL.

Methods. This study was a cross-sectional study of 52 children and adolescents with ALL who were undergoing chemotherapy at the Cipto Mangunkusumo Hospital (CMH). Blood sampling and plain radiographs of the spine were performed to assess bone health parameters, as well as dual energy X-ray absorptiometry (DEXA) examination to assess bone mineral density. Logistic regression analysis was used to analyze the association between the cumulative dose of methotrexate and steroids on the incidence of secondary osteoporosis.

Result. The median age of the subjects was 10 (7-14) years with 54% men (n=52). The incidence of secondary osteoporosis was 6/52 (11.5%) and low bone mineral density 11/52 (21.2%). There was no association between the cumulative dose of steroids (adjusted PR 1.501 [0.124-18.124], p=0.75) and the cumulative dose of methotrexate (adjusted PR 0.071 [0.005-0.951], p=0.05) and the incidence of secondary osteoporosis. None of the confounding factors (pubertal status, vitamin D levels, income level, age, and sex) were associated with secondary osteoporosis. Patient aged below 10 years old, have prepubertal status, and with low vitamin D serum tends to have osteoporosis more likely.

Conclusion. There was no statistically significant relationship between the cumulative dose of steroids and/or methotrexate on secondary osteoporosis in children and adolescents with ALL."

"ABSTRAKLatar belakang : Prevalens terjadinya malnutrisi bervariasi pada berbagai siklus kemoterapi LLA. Penelitian di Malaysia mendapatkan anak LLA pasca-kemoterapi fase induksi cenderung mengalami obesitas atau status gizi lebih. Penyebab malnutrisi pada anak LLA dapat dipengaruhi oleh berbagai faktor. Perubahan status gizi selama kemoterapi dapat memengaruhi luaran kemoterapi.Tujuan: mengetahui faktor-faktor yang memengaruhi perbaikan status gizi anak LLA setelah kemoterapi fase konsolidasi, serta pengaruhnya terhadap luaran kemoterapi, sehingga dapat dipakai sebagai masukan untuk upaya mengatasi malnutrisi pada anak LLA.Metode : Penelitian ini dengan uji retrospektif, di Rumah sakit Cipto Mangunkusumo, selama tahun 2016-2018. Total sampling pada pasien leukemia limfoblastik akut yang terdiagnosis, dan menjalani kemoterapi di RSCM hingga fase konsolidasi.Hasil : Seratus empat puluh satu subyek pasien anak LLA diikutsertakan dalam penelitian ini. Terdapat 69,5% subyek mengalami perbaikan status gizi, dan 30,5% mengalami perburukan status gizi, dengan 60% perburukan ke arah overnutrition pasca-kemoterapi fase konsolidasi. Faktor risiko independen terhadap terjadinya perbaikan status gizi pasca-kemoterapi fase konsolidasi ialah tidak timbulnya efek samping kemoterapi (RR 1,36, 95% IK 1,02 - 1,81). Jenis makanan dan cara pemberian makan tidak memengaruhi perubahan status gizi anak LLA pasca-fase konsolidasi. Terdapat hubungan antara perbaikan status gizi anak LLA pasca-fase konsolidasi dengan kejadian remisi (RR 1,24, 95% IK 1,03 - 1,5).Simpulan : Status gizi pasca-kemoterapi fase konsolidasi mengalami perbaikan dibandingkan sebelum kemoterapi, sedangkan yang mengalami perburukan status gizi cenderung mengalami overnutrition. Perbaikan status gizi anak LLA pasca-kemoterapi fase konsolidasi dipengaruhi oleh tidak timbulnya efek samping kemoterapi. Terdapat hubungan antara perbaikan status gizi anak LLA pasca-kemoterapi fase konsolidasi dengan kejadian remisi.

---

ABSTRACTBackground: Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. The prevalence of malnutrition varies in phase of ALL chemotherapy. Study in Malaysia showed ALL children after induction phase of chemotherapy tended to be obese or overweight. The causes of malnutrition in ALL children can be influenced by various factors. Changes in nutritional status during chemotherapy can affect the outcome of chemotherapy.Aim: To investigate factors that influence nutritional status improvement of ALL children after consolidation phase, as well as the effect on the outcomes of chemotherapy, so it can be used as an input to overcome malnutrition in ALL children.Method: A retrospective design was performed in Cipto Mangunkusumo Hospital from 2016 until 2018. Total sampling in patients with acute lymphoblastic leukemia who was diagnosed and started chemotherapy at Cipto Mangunkusumo Hospital until the consolidation phase.Result: A total of 141 subjects were included in this study. After consolidation phase, 69.5% of subjects experienced nutritional status improvements, and 30.5% worsened, of which 60% become over nutrition post-consolidation phase. Independent risk factor for the improvement of nutritional status after consolidation phase was the absence of chemotherapy side effects (RR 1.36, 95% CI 1.02 - 1.81). There were no association between type of food and route of feeding with nutritional status improvement of ALL children after consolidation phase. There was association between improvement in nutritional status of ALL children after consolidation phase with the incidence of remission (RR 1.24, 95% CI 1.03 - 1.5).Conclusion: Nutritional status at post-consolidation phase has improved compared to pre- chemotherapy, while those who worsening nutritional status tend to overnutrition. The absence of chemotherapy side effects affects nutritional status improvement of ALL children after consolidation phase. There is a relationship between nutritional status improvement of ALL children after consolidation phase with the incidence of remission."

"[ABSTRAKLatar Belakang: Angka kesintasan LLA pada anak di negara berkembang masih tertinggal dibanding negara maju. Ketepatan diagnosis dan stratifikasi risiko pasien LLA merupakan hal penting yang perlu dievaluasi sebagai langkah awal untuk meningkatkan kesintasan. Di negara maju ketepatan diagnosis dan stratifikasi risiko didasarkan atas hasil pemeriksaan morfologi, imunofenotiping, sitogenetik, dan molekular. Di Indonesia, hal tersebut belum dapat dilakukan sepenuhnya karena keterbatasan biaya dan fasilitas. Untuk itu, perlu kriteria stratifikasi berdasarkan klinis dan laboratorium sederhana tetapi mampu mendekati stratifikasi molekular. Respons steroid merupakan faktor prognostik kuat dalam memprediksi kejadian relaps dan memengaruhi angka kesintasan. Penambahan variabel respons steroid pada stratifikasi RSCM (stratifikasi modifikasi) diharapkan dapat mendekati kemampuan stratifikasi molekular sebagai baku emas.Metode: Penelitian kohort prospektif selama 6 bulan dilakukan di Departemen Ilmu Kesehatan Anak FKUI-RSCM pada Januari 2013 - September 2014. Subjek adalah pasienbaruterdiagnosis LLAkemudiandikelompokkanmenjadirisikobiasa(RB)danrisiko tinggi (RT) berdasarkan kriteria stratifikasi RSCM (usia, jumlah leukosit, massa mediastinum dan infiltrasi SSP). Subjek dengan RB mendapat prednison (60 mg/kgBB/hari) dan RT mendapat deksametason (6 mg/kgBB/hari) selama 7 hari. Respons steroid dievaluasi pada hari ke-8, dengan menghitung blas di darah tepi. Respons baik bila jumlah blas < 1.000/μL dan respons buruk bila jumlah blas > 1.000/μL. Subjek dengan respons buruk dikelompokkan RT sesuai stratifikasi risiko yang baru (stratifikasi modifikasi). Evaluasi remisi fase induksi dilakukan setelah 6 minggu pemberian kemoterapi berdasarkan persentase blas dan minimal residual disease (MRD) sumsum tulang. Kriteria risiko tinggi pada stratifikasi molekular bila terdapat fusi gen E2A-PBX1, MLL-AF4, dan BCR-ABL, sedangkan risiko biasa bila terdapat fusi gen TEL-AML1.Hasil Penelitian: Pada penelitian ini diikutsertakan 73 subjek dengan rerata usia subjek 5,5 (SB ± 3,8) tahun. Subjek lelaki (65,8%) lebih banyak dibanding perempuan (34,2%). Gejala klinis yang sering ditemukan adalah pucat sebanyak 65 (89%), demam 53 (72,6%), nyeri tulang 51 (70%), dan hepatomegali 51 (70%) subjek. Hasil pemeriksaan imunofenotiping mendapatkan 77,1% sel B, 17,1% sel T, dan 5,7% sel campuran. Ketidaksesuaian remisi fase induksi berdasarkan morfologi dan MRD sebesar 15,2%. Stratifikasi RSCM maupun modifikasi tidak berkorelasi dengan stratifikasi molekular (r = 1,1; p = 0,6). Angka kesintasan berdasarkan stratifikasi molekular (79%) lebih tinggi dibandingkan stratifikasi RSCM (68,5%) maupun modifikasi (69,6%).Simpulan: Stratifikasi modifikasi menunjukkan kemampuan yang sama dengan stratifikasi RSCM dibandingkan stratifikasi molekular. Angka kesintasan berdasarkan stratifikasi molekular lebih tinggi dibandingkan stratifikasi RSCM dan modifikasi.;

---

ABSTRACTIntroduction: Survival rate of children with ALL in developing countries remains lower compared to developed countries. Diagnosis and risk stratification are important to determine survival rates. Diagnosis and risk stratification in developed countries are based on morphology, immunophenotyping, cytogenetic, and molecular examination of bone marrow while in Indonesia most of those examinations are not available due to financial and facilities limitation. Therefore, we need to develop stratification criteria based on clinical and laboratory assessment which is comparable to molecular stratification. Response to steroid is a strong predictor of relapse and survival rates in ALL. The aim of the study is to develop new stratification to improve accuracy in predicting relapse rate and increase survival rate, by adding steroid response variable to current CMH stratification, in comparison with molecular stratification as gold standard.Methods: A prospective study was conducted at Pediatric Hematology-Oncology Division, Department of Child Health, FMUI-CMH on January 2013 ? September 2014. Morphology, immunophenotyping, cytogenetic and molecular assessment were performed. Patient was stratified into standard risk (SR) and high risk (HR) based on CMH stratification criteria (based on age, WBC, mediastinal mass and CNS infiltration) and given steroid (prednisone or dexamethasone) for 7 days. Steroid response was evaluated at day 8, good response if peripheral blast count < 1,000/μL and poor response if > 1,000/μL. Poor responders were moved to HR group in new stratification (modified stratification). Bone marrow aspiration and minimal residual disease (MRD) detection were perfomed after induction phase to evaluate remission and patient was observed for 6 months. High risk criteria based on molecular stratification are E2A-PBX1, MLL-AF4 and BCR-ABL fusion genes, while standard risk is TEL-AML1.Results: A total of 73 newly diagnosed ALL patients were enrolled in this study. The mean age was 5.5 (SD ± 3.8) years. Incidence in male (65.8%) is higher than female (34.2%). Clinical characteristics are pale (89%), fever (72.6%), bone pain (70%), hepatomegaly (70%), bleeding (42.5%), lymphadenopathy (49.0%), and splenomegaly (46.6%). Immunophenotyping result was 77.1% for B-lineage; 17.1% T-lineage; and 5.7% mixed lineage. Minimal residual disease detection from 33 patients showed no difference in remission between CMH and modified stratification. Four patients were moved to HR after evaluation of steroid response. We found discrepancy of remission induction results based on morphology and MRD in 15.2% subjects. Survival rate for CMH, modified, and molecular stratification were 68.5%, 69.6%, and 75.5%, respectively. Cipto Mangunkusumo Hospital and modified stratification were not correlated with molecular stratification as the gold standard (r = 1.1 ; p = 0.6).Conclusions: Modified stratification had similar accuracy with CMH stratification compare to molecular stratification in predicting survival rate of ALL children. Remission based on MRD detection between the two stratification was also similar. Survival rate by molecular stratification was higher compared to CMH or modified stratification.;Introduction: Survival rate of children with ALL in developing countries remains lower compared to developed countries. Diagnosis and risk stratification are important to determine survival rates. Diagnosis and risk stratification in developed countries are based on morphology, immunophenotyping, cytogenetic, and molecular examination of bone marrow while in Indonesia most of those examinations are not available due to financial and facilities limitation. Therefore, we need to develop stratification criteria based on clinical and laboratory assessment which is comparable to molecular stratification. Response to steroid is a strong predictor of relapse and survival rates in ALL. The aim of the study is to develop new stratification to improve accuracy in predicting relapse rate and increase survival rate, by adding steroid response variable to current CMH stratification, in comparison with molecular stratification as gold standard.Methods: A prospective study was conducted at Pediatric Hematology-Oncology Division, Department of Child Health, FMUI-CMH on January 2013 ? September 2014. Morphology, immunophenotyping, cytogenetic and molecular assessment were performed. Patient was stratified into standard risk (SR) and high risk (HR) based on CMH stratification criteria (based on age, WBC, mediastinal mass and CNS infiltration) and given steroid (prednisone or dexamethasone) for 7 days. Steroid response was evaluated at day 8, good response if peripheral blast count < 1,000/μL and poor response if > 1,000/μL. Poor responders were moved to HR group in new stratification (modified stratification). Bone marrow aspiration and minimal residual disease (MRD) detection were perfomed after induction phase to evaluate remission and patient was observed for 6 months. High risk criteria based on molecular stratification are E2A-PBX1, MLL-AF4 and BCR-ABL fusion genes, while standard risk is TEL-AML1.Results: A total of 73 newly diagnosed ALL patients were enrolled in this study. The mean age was 5.5 (SD ± 3.8) years. Incidence in male (65.8%) is higher than female (34.2%). Clinical characteristics are pale (89%), fever (72.6%), bone pain (70%), hepatomegaly (70%), bleeding (42.5%), lymphadenopathy (49.0%), and splenomegaly (46.6%). Immunophenotyping result was 77.1% for B-lineage; 17.1% T-lineage; and 5.7% mixed lineage. Minimal residual disease detection from 33 patients showed no difference in remission between CMH and modified stratification. Four patients were moved to HR after evaluation of steroid response. We found discrepancy of remission induction results based on morphology and MRD in 15.2% subjects. Survival rate for CMH, modified, and molecular stratification were 68.5%, 69.6%, and 75.5%, respectively. Cipto Mangunkusumo Hospital and modified stratification were not correlated with molecular stratification as the gold standard (r = 1.1 ; p = 0.6).Conclusions: Modified stratification had similar accuracy with CMH stratification compare to molecular stratification in predicting survival rate of ALL children. Remission based on MRD detection between the two stratification was also similar. Survival rate by molecular stratification was higher compared to CMH or modified stratification.;Introduction: Survival rate of children with ALL in developing countries remains lower compared to developed countries. Diagnosis and risk stratification are important to determine survival rates. Diagnosis and risk stratification in developed countries are based on morphology, immunophenotyping, cytogenetic, and molecular examination of bone marrow while in Indonesia most of those examinations are not available due to financial and facilities limitation. Therefore, we need to develop stratification criteria based on clinical and laboratory assessment which is comparable to molecular stratification. Response to steroid is a strong predictor of relapse and survival rates in ALL. The aim of the study is to develop new stratification to improve accuracy in predicting relapse rate and increase survival rate, by adding steroid response variable to current CMH stratification, in comparison with molecular stratification as gold standard.Methods: A prospective study was conducted at Pediatric Hematology-Oncology Division, Department of Child Health, FMUI-CMH on January 2013 ? September 2014. Morphology, immunophenotyping, cytogenetic and molecular assessment were performed. Patient was stratified into standard risk (SR) and high risk (HR) based on CMH stratification criteria (based on age, WBC, mediastinal mass and CNS infiltration) and given steroid (prednisone or dexamethasone) for 7 days. Steroid response was evaluated at day 8, good response if peripheral blast count < 1,000/μL and poor response if > 1,000/μL. Poor responders were moved to HR group in new stratification (modified stratification). Bone marrow aspiration and minimal residual disease (MRD) detection were perfomed after induction phase to evaluate remission and patient was observed for 6 months. High risk criteria based on molecular stratification are E2A-PBX1, MLL-AF4 and BCR-ABL fusion genes, while standard risk is TEL-AML1.Results: A total of 73 newly diagnosed ALL patients were enrolled in this study. The mean age was 5.5 (SD ± 3.8) years. Incidence in male (65.8%) is higher than female (34.2%). Clinical characteristics are pale (89%), fever (72.6%), bone pain (70%), hepatomegaly (70%), bleeding (42.5%), lymphadenopathy (49.0%), and splenomegaly (46.6%). Immunophenotyping result was 77.1% for B-lineage; 17.1% T-lineage; and 5.7% mixed lineage. Minimal residual disease detection from 33 patients showed no difference in remission between CMH and modified stratification. Four patients were moved to HR after evaluation of steroid response. We found discrepancy of remission induction results based on morphology and MRD in 15.2% subjects. Survival rate for CMH, modified, and molecular stratification were 68.5%, 69.6%, and 75.5%, respectively. Cipto Mangunkusumo Hospital and modified stratification were not correlated with molecular stratification as the gold standard (r = 1.1 ; p = 0.6).Conclusions: Modified stratification had similar accuracy with CMH stratification compare to molecular stratification in predicting survival rate of ALL children. Remission based on MRD detection between the two stratification was also similar. Survival rate by molecular stratification was higher compared to CMH or modified stratification., Introduction: Survival rate of children with ALL in developing countries remains lower compared to developed countries. Diagnosis and risk stratification are important to determine survival rates. Diagnosis and risk stratification in developed countries are based on morphology, immunophenotyping, cytogenetic, and molecular examination of bone marrow while in Indonesia most of those examinations are not available due to financial and facilities limitation. Therefore, we need to develop stratification criteria based on clinical and laboratory assessment which is comparable to molecular stratification. Response to steroid is a strong predictor of relapse and survival rates in ALL. The aim of the study is to develop new stratification to improve accuracy in predicting relapse rate and increase survival rate, by adding steroid response variable to current CMH stratification, in comparison with molecular stratification as gold standard.Methods: A prospective study was conducted at Pediatric Hematology-Oncology Division, Department of Child Health, FMUI-CMH on January 2013 – September 2014. Morphology, immunophenotyping, cytogenetic and molecular assessment were performed. Patient was stratified into standard risk (SR) and high risk (HR) based on CMH stratification criteria (based on age, WBC, mediastinal mass and CNS infiltration) and given steroid (prednisone or dexamethasone) for 7 days. Steroid response was evaluated at day 8, good response if peripheral blast count < 1,000/μL and poor response if > 1,000/μL. Poor responders were moved to HR group in new stratification (modified stratification). Bone marrow aspiration and minimal residual disease (MRD) detection were perfomed after induction phase to evaluate remission and patient was observed for 6 months. High risk criteria based on molecular stratification are E2A-PBX1, MLL-AF4 and BCR-ABL fusion genes, while standard risk is TEL-AML1.Results: A total of 73 newly diagnosed ALL patients were enrolled in this study. The mean age was 5.5 (SD ± 3.8) years. Incidence in male (65.8%) is higher than female (34.2%). Clinical characteristics are pale (89%), fever (72.6%), bone pain (70%), hepatomegaly (70%), bleeding (42.5%), lymphadenopathy (49.0%), and splenomegaly (46.6%). Immunophenotyping result was 77.1% for B-lineage; 17.1% T-lineage; and 5.7% mixed lineage. Minimal residual disease detection from 33 patients showed no difference in remission between CMH and modified stratification. Four patients were moved to HR after evaluation of steroid response. We found discrepancy of remission induction results based on morphology and MRD in 15.2% subjects. Survival rate for CMH, modified, and molecular stratification were 68.5%, 69.6%, and 75.5%, respectively. Cipto Mangunkusumo Hospital and modified stratification were not correlated with molecular stratification as the gold standard (r = 1.1 ; p = 0.6).Conclusions: Modified stratification had similar accuracy with CMH stratification compare to molecular stratification in predicting survival rate of ALL children. Remission based on MRD detection between the two stratification was also similar. Survival rate by molecular stratification was higher compared to CMH or modified stratification.]"

"ABSTRAKLatar Belakang: Glukokortikoid berperan penting dalam pengobatan leukemia limfoblastik akut (LLA), namun dapat menimbulkan efek samping berupa gangguan pada aksis hipotalamus-hipofisis-adrenal (HHA). Penekanan aksis HHA menyebabkan respons kortisol terhadap stres berkurang sehingga merupakan penyebab morbiditas dan mortalitas LLA pada anak.Tujuan: Mengetahui fungsi kelenjar adrenal pada anak dengan LLA setelah kemoterapi fase induksi dengan glukokortikoid dosis tinggi.Metode: Penelitian bersifat before and after dengan menilai fungsi kelenjar adrenal pada pasien LLA baru sebelum kemoterapi fase induksi yang mendapatkan prednison atau deksametason oral selama 6 minggu dan setelah tapering off glukokortikoid selama 1 minggu. Sebanyak 20 subjek dari 4 rumah sakit di Jakarta direkrut dan dianalisis. Penilaian fungsi kelenjar adrenal dilakukan dengan uji stimulasi ACTH dosis standar (250 μg).Hasil: Dari 20 subjek, terdapat 14 subjek yang mengalami insufisiensi adrenal pasca-kemoterapi fase induksi berdasarkan kriteria peningkatan kortisol pasca-uji <18 μg/dL. Nilai median kadar kortisol pra-uji dan pasca-uji sebelum kemoterapi berturut-turut adalah 14,72 μg/dL (2,01 – 46,1 μg/dL) dan 29,29 μg/dL (21,65 – 55,15 μg/dL), dan kadar kortisol pra-uji dan pasca-uji sesudah kemoterapi berturut-turut adalah 5,87 μg/dL (0,2 – 20,53 μg/dL) dan 10,49 μg/dL (0,33 – 28,69 μg/dL). Gejala klinis tidak berbeda bermakna antara subjek yang mengalami insufisiensi adrenal dengan yang mereka tidak mengalami insufisiensi adrenal.Simpulan: Sebanyak 14 dari 20 subjek mengalami insufisiensi adrenal setelah mendapatkan glukokortikoid dosis tinggi selama kemoterapi fase induksi walaupun telah tapering off selama 1 minggu. Tidak ada gejala klinis yang spesifik ditemukan berkaitan dengan insufisiensi adrenal.

---

ABSTRACTBackground: Glucocorticoids play an important role in the treatment of acute lymphoblastic leukemia (ALL), but can cause side effects such as suppression of the hypothalamic-pituitary-adrenal (HHA) axis. Suppression of the HHA axis causes adrenal insufficiency and disturb cortisol response to stress and may be a cause of morbidity and mortality in children ALL.Objective: To evaluate adrenal function in children with ALL after induction chemotherapy with high dose glucocorticoids.Methods: Twenty children with ALL were evaluated using standard dose (250 μg) adrenocorticotropin hormone (ACTH) test before and after their treatment with prednisone or dexamethasone for 6 weeks of induction phase followed by 1 week tapering off.Results: Adrenal insufficiency was found in 14 of 20 subjects after induction phase followed by 1-week tapering off based on cortisol post-stimulation <18 μg/dL. The median of cortisol pre- and post-stimulation before induction phase are 14,72 μg/dL (2,01 – 46,1 μg/dL) and 29,29 μg/dL (21,65 – 55,15 μg/dL), dan cortisol pre- and post-stimulation after induction phase are 5,87 μg/dL (0,2 – 20,53 μg/dL) dan 10,49 μg/dL (0,33 – 28,69 μg/dL). Clinical signs and symptoms did not differ between those who had adrenal insufficiency with those who did not have adrenal insufficiency.Conclusions: Fourteen out of 20 children with ALL developed adrenal insufficiency after a 6-week induction therapy with glucocorticoids and 1-week tapering off. No specific clinical signs and symptoms were related to adrenal insufficiency."

"ABSTRAKLatar belakang: Peningkatan enzim transaminase sering ditemukan pada anak dengan leukemia limfoblastik akut LLA dalam kemoterapi fase pemeliharaan. Belum ada penelitian terkait pemberian vitamin E pada anak LLA dengan kondisi tersebut di Indonesia. Tujuan: Mengetahui prevalens, karakteristik, dan pengaruh pemberian vitamin E terhadap perbaikan kadar enzim transaminase pada anak LLA dalam kemoterapi fase pemeliharaan. Metode: Uji klinis acak tersamar tunggal, membandingkan vitamin E dosis antioksidan dengan plasebo pada anak LLA yang mengalami peningkatan enzim transaminase bulan Agustus-Desember 2017 di Poliklinik Hematologi dan Onkologi Rumah Sakit Cipto Mangunkusumo. Enzim transaminase dievaluasi setelah 3 dan 5 minggu intervensi dan perbaikan didefinisikan bila menurun ge;20 . Hasil: Terdapat 33 kejadian peningkatan enzim transaminase, 17 vitamin E dan 16 plasebo. Prevalens 41,2 , karakteristik pasien predominan laki-laki, usia 2,5-5x. Vitamin E dibandingkan plasebo setelah 3 minggu P=0,601; RR=0,93; IK 95 0,73-1,16 dan 5 minggu P= 0,103; RR= 0,81; IK 95 0,64-1,03 . Kesimpulan: Pemberian Vitamin E dibandingkan plasebo pada anak LLA dalam kemoterapi fase pemeliharaan setelah 3 dan 5 minggu tidak berbeda bermakna, namun kelompok vitamin E terdapat kecenderungan perbaikan kadar enzim transaminase.

---

ABSTRACTBackground Aminotransferase enzyme rsquo s elevation is a common complication associated maintenance chemotherapy in pediatric acute lymphoblastic leukemia ALL . Vitamin E is used as therapy but none research has been done on this issue in Indonesia. Objectives To identify the prevalence, characteristics of patients and the effect of vitamin E on aminotransferase enzyme rsquo s improvement in pediatric ALL during maintenance chemotherapy. Methods A randomized single blind controlled trial of antioxidant dose vitamin E versus placebo in pediatric ALL during maintenance chemotherapy with aminotransferase enzyme rsquo s elevation was conducted on August December 2017 at Hematology and Oncology clinic Cipto Mangunkusumo hospital. Aminotransferase enzymes were evaluated after intervention for 3 and 5 weeks. Improvement was defined as a decrease ge 20 of baseline. Results There were 33 events, 17 vitamin E and 16 placebo. Prevalence was 41,2 , characteristics were predominated boys, 2,5 5x. There were no statistical difference in aminotranferase enzyme rsquo s improvement after 3 weeks intervention P 0,601 RR 0,93 CI 95 0,73 1,16 and 5 weeks intervention P 0,103 RR 0,81 CI 95 0,64 1,03 . Conclusion Antioxidant dose of vitamin E tends to decrease aminotransferase enzyme but not statistically significant. "

"Leukemia limfoblastik akut (LLA) adalah keganasan yang paling sering terjadi pada anak-anak. Angka kesembuhan yang besar terjadi akibat terapi kanker saat ini, namun respon toksik yang terkait dan pembentukan radikal bebas meningkatkan angka kematian akibat pengobatan daripada kematian akibat penyakitnya itu sendiri. Komplikasi kemoterapi meningkatkan rasa ingin tahu dokter untuk mempelajari penggunaan antioksidan sebagai pengobatan tambahan pada kanker. Penelitian ini bertujuan untuk mengevaluasi peran N-asetilsistein ​​(NAS) sebagai terapi antioksidan pada anak-anak dengan LLA SR (standard risk) selama fase induksi kemoterapi, dan kemungkinan peran mereka dalam pencegahan dan pengendalian komplikasi hati terkait dengan penggunaan agen kemoterapi. Sebuah uji klinis acak tersamar tunggal NAS dibandingkan dengan plasebo yang dilakukan pada pasien anak Departemen Ilmu Kesehatan Anak Divisi Hematologi dan Onkologi di Rumah Sakit Cipto Mangunkusumo, Jakarta. Penelitian ini dilakukan pada 11 pasien anak-anak usia mereka berkisar antara 2 dan 10 tahun dengan LLA SR yang menjalani kemoterapi fase induksi dan memenuhi kriteria inklusi. Pasien secara acak dialokasikan ke dalam dua kelompok, NAS atau kelompok plasebo. Mereka dievaluasi secara klinis untuk terjadinya komplikasi dan sampel darah dikumpulkan sebagai parameter laboratorium (plasma malondialdehid (MDA), enzim transaminase, dan bilirubin). Sebanyak 11 subjek dilakukan analisis yang terdiri dari 6 pada kelompok n-asetilsistein dan 5 pada kelompok plasebo. Karakteristik subjek didominasi oleh anak laki-laki dengan status gizi kurang. Kadar rerata MDA cenderung mengalami penurunan, sebanyak tiga subjek dari enam subjek pada kelompok perlakuan dan tiga subjek dari lima subjek pada kelompok plasebo. Insidens peningkatan kadar enzim transaminase sebesar 25%. Tidak terjadi kejadian kolestasis pada subjek penelitian. Pengobatan NAS ​​berdasarkan dosis antioksidan cenderung menurunkan kadar MDA, dan mencegah peningkatan enzim transaminase, dan bilirubin.

---

Acute lymphoblastic leukemia (ALL) is the most commonly malignancy in children. Cancer therapies have experienced great success nowadays, yet the associated toxic response and free radicals formation have resulted in significant number of treatment-induced deaths rather than disease-induced fatalities. Complications of chemotherapy increases physicians curiosity to study antioxidant use as adjunctive treatment in cancer. This study aims to evaluate the role of N-acetylcysteine (NAC) as antioxidant therapy in children with ALL during the induction phases of chemotherapy, and their possible role in prevention and control of hepatic complications associated with the use of chemotherapic agents. A randomized single-blind clinical trial of NAC in comparison with placebo conducted in hematology and oncology pediatric patient of Cipto Mangunkusumo Hospital, Jakarta. The study was performed in 11 pediatric patients with ALL with their ages ranging between 2 and 10 years, undergoing induction phase chemotherapy that fulfilled the inclusion criteria consecutively. Patient were randomly allocated into of two groups, NAC or placebo group. They were evaluated clinically for the occurance of complications and blood samples were collected as the laboratory parameters (plasma malondyaldehide (MDA), transaminase enzyme, and bilirubin). A total 11 participants were included in analysis consisted of 6 in n-acetylcysteine group and 5 in placebo group. Characteristics of subject were predominated by boys and moderate malnourished. Mean MDA levels tended to decrease, as many as three subjects from six subjects in the NAC group and three subjects from five subjects in the placebo group. Incidence of increased levels of the transaminase enzyme by 25%. There was no cholestasis events in the study subjects. NAS treatment based on antioxidant doses tends to reduce MDA levels, and prevent the increase in the transaminase enzyme and bilirubin."

"Leukemia limfoblastik akut (ALL) adalah jenis kanker yang paling umum pada anak-anak. Nyeri dan kelelahan berhubungan dengan faktor-faktor kanker dan perawatannya. Tujuan dari penelitian ini adalah untuk menemukan hubungan antara kualitas nyeri dan kelelahan pada anak-anak dengan ALL 1-3 hari setelah kemoterapi. Penelitian ini menggunakan desain cross sectional dan menggunakan teknik consequtive sampling. Total sampel adalah 44 anak-anak dengan ALL (7-18 tahun) di Jakarta. Alat ukur yang digunakan dalam penelitian ini adalah kuesioner Simple Pain Inventory (BPI) untuk mengukur kualitas nyeri dan Kelelahan Onkologi Anak-Allen (FOA-A) untuk mengukur kelelahan. Nilai rata-rata kualitas nyeri adalah 1,63932 dan nilai rata-rata kelelahan adalah 9,25. Hasil penelitian ini menunjukkan bahwa ada hubungan yang signifikan antara kualitas nyeri dan kelelahan (p = 0,006), status kambuh dan kelelahan (p = 0,058), dan antara seseorang yang menemani anak-anak dan kelelahan (p = 0,016). Hasil penelitian ini merekomendasikan pentingnya penilaian nyeri lebih lanjut dan pengobatan kombinasi antara farmakologi dan nyeri non-farmakologi setelah kemoterapi untuk mengurangi kelelahan pada anak-anak dengan kanker.

---

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Pain and fatigue are related to cancer factors and their treatments. The aim of this study was to find an association between pain quality and fatigue in children with ALL 1-3 days after chemotherapy. This research uses cross sectional design and uses consequtive sampling technique. The total sample was 44 children with ALL (7-18 years) in Jakarta. The measuring instrument used in this study was a Simple Pain Inventory (BPI) questionnaire to measure the quality of pain and Fatigue Oncology of Children-Allen (FOA-A) to measure fatigue. The average value of pain quality is 1.63932 and the average value of fatigue is 9.25.

The results of this study indicate that there is a significant relationship between quality of pain and fatigue (p = 0.006), relapse and fatigue status (p = 0.058), and between someone who accompanies children and fatigue (p = 0.016). The results of this study recommend the importance of further pain assessment and combination treatment between pharmacology and non-pharmacological pain after chemotherapy to reduce fatigue in children with cancer."

"Latar belakang: Leukemia limfoblastik akut (LLA) merupakan kanker tersering pada anak. Berbagai studi mendapatkan bahwa vitamin D berperan dalam pencegahan beberapa jenis kanker. Belum ada studi yang menilai hubungan status vitamin D dengan penyakit LLA pada anak di Indonesia.Tujuan: Untukmengetahui hubungan antara status vitamin D dengan penyakit LLA pada anak. Metode: Studi potong lintang pada 40 anak LLA yang baru terdiagnosis dan 40 anak sehat yang sesuai umur dan jenis kelamin. Pasien LLA diambil secara consecutive sampling di RSUPN Dr. Cipto Mangunkusumo Jakarta dan RSUP Dr. M. Djamil Padang. Status vitamin D diklasifikasikan berdasarkan rekomendasi Institute of Medicine yaitu defisiensi bila kadar < 12 ng/mL, insufisiensi 12 - <20 ng/mL, dan normal 20-100 ng/mL. Data dianalisa menggunakan uji Chi-Squaredan independent sample t-test, dengan kemaknaan p <0,05.Hasil: Terdapat 22 (55%) anak laki-laki pada masing-masing kelompok dan kelompok usia 1-4 tahun merupakan kelompok terbanyak (48%). Mayoritas anak LLA memiliki status vitamin D normal (78%), demikian juga kelompok kontrol (63%). Terdapat 3(7%) dan 6(15%) anak LLA serta 1(2%) dan 14(35%) anak sehat memiliki status defisiensi dan insufisiensi berturut-turut dengan p =0,14. Rerata kadar vitamin D anak LLA adalah 25,1(7,6) ng/mL dan anak sehat 21,9(5,67) ng/mL, dengan perbedaan rerata 3,14 (IK95% 0,15-6,13) dan p =0,04.Simpulan:Mayoritas anak LLA yang baru terdiagnosis memiliki status vitamin D normal. Rerata kadar vitamin D anak LLA lebih tinggi bermakna dari anak sehat, namun tidak terdapat hubungan yang bermakna antara status vitamin D dan penyakit LLA pada anak.

---

Background:Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Various studies have found that vitamin D plays a role in the prevention of several types of cancer. Currently, there is no study in Indonesia that assess association between vitamin D status and pediatric ALL

Objective:To determine association between vitamin D status and pediatric ALL.

Methods:A cross-sectional study of 40 newly diagnosed ALL children and 40 age-and sex-matched healthy children. ALL patients were taken by consecutive sampling at Dr. Cipto Mangunkusumo Hospital Jakarta and Dr. M. Djamil Hospital Padang. Vitamin D status is classified based on Institute of Medicine recommendations; deficiency <12 ng/mL, insufficiency 12 - <20 ng/mL, and normal 20-100 ng/mL. Data were analyzed using Chi-square test and independent sample t-test. A p-value <0.05 is considered to be statistically significant.

Results: There were 22 (55%) boys in each group and the group 1-4 years was the most age group (48%). Majority of ALL children had normal vitamin D status (78%) and also in healthy children (63%). There were 3(7%) and 6(15%) ALL children as well as 1(2%) and 14(35%) healthy children had deficiency and insufficiency status consecutively, with p value =0.14. The mean vitamin D level of ALL children and healthy children were 25.1 (7.6) ng/mL and was 21.9 (5.67) ng/mL consecutively, with mean difference of 3.14 (95% CI 0.15-6.13) and p value =0.04..

Conclusion:The majority of newly diagnosed ALL children have normal vitamin D status. The mean vitamin D levels of ALL children was significantly higher than healthy children, however there was no significant association between vitamin D status and ALL in children."

"Latar belakang: Anak yang menderita Leukemia Limfoblastik Akut LLA menunjukkan peningkatan sistem imun pada akhir perawatan kemoterapi. sIgA merupakan hasil dari sistem imun yang ada pada saliva. Tujuan: Menganalisis perbedaan kadar sIgA saliva antara anak LLA fase pemeliharaan dengan gingivitis dan anak sehat dengan gingivitis. Metode Penelitian: Saliva diambil dari anak LLA dan anak sehat. selanjutnya kadar sIgA saliva diukur dengan metode ELISA. Hasil: Signifikansi Mann-Whitney menunjukkan besar 0.157 p>0.05 . Kesimpulan: Terdapat perbedaan kadar sIgA saliva antara anak LLA fase pemeliharaan dengan gingivitis dan anak sehat dengan gingivitis, namun tidak signifikan.

---

Background: Acute Lymphoblastic Leukemia ALL children shows an increasing of immune system in the late phase of chemotherapy. sIgA is a product of immune system in saliva.

Aim: To analyze salivary sIgA difference between ALL children in maintenance phase and healthy children with gingivitis.

Method: Saliva was collected from ALL and healthy children. The salivary sIgA level was then measured with ELISA method.

Results: Mann Whitney significance shows the number 0.157 p 0.05 .

Conclusion There is a difference in salivary sIgA levels among ALL children in the maintenance phase and healthy children with gingivitis, but the difference is not significant."